Home / Market News / $GSK

$GSK news and market catalysts

The 37 most recent market catalysts affecting $GSK, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

37 catalysts 9 high impact 25 bullish 7 bearish Pharmaceuticals
Nov 19, 2026 Corporate Catalyst Bullish Impact 55
GSK Receives Orphan Drug Designation for Gastrointestinal Cancer Drug in Japan
GSK has secured orphan drug designation in Japan for Velzatinib, a drug targeting gastrointestinal stromal tumors. This designation is a positive development as it provides incenti…
Nov 17, 2026 Corporate Catalyst Bullish Impact 75
FDA Grants Accelerated Approval to GSK's Nelkarmi for ALK-Positive Lung Cancer
GSK has received accelerated FDA approval for Nelkarmi, a new treatment for ALK-positive lung cancer. This is a crucial development as it validates GSK's R&D efforts in oncology an…
Nov 16, 2026 Corporate Catalyst Bullish Impact 55
GSK's ViiV Healthcare Receives EMA Committee Recommendation to Expand HIV Drug Use
ViiV Healthcare, a company majority-owned by GSK, has received a positive recommendation from an EMA committee to expand the use of its HIV medications. This is a significant regul…
Nov 13, 2026 Corporate Catalyst Bullish Impact 65
GSK's Meningococcal Disease Vaccine Receives EU Recommendation for Newborns
GSK announced that its meningococcal disease vaccine has received a regulatory recommendation in the European Union for use in newborns. This is a significant step as it opens up a…
Nov 9, 2026 Corporate Catalyst Neutral Impact 55
GSK Outlines R&D Strategy at Guggenheim Healthcare Innovation Conference
GSK presented its R&D strategy at the Guggenheim Healthcare Innovation Conference, detailing its focus on human-validated targets, biomarker-led trials, and combination therapies f…
Nov 3, 2026 Corporate Catalyst Bullish Impact 55
GSK Enters Strategic Scientific Collaboration with Alamar Biosciences
GSK has entered a strategic scientific collaboration with Alamar Biosciences to leverage Alamar's NULISA platform for a large-scale study. This partnership is significant because i…
Nov 3, 2026 Corporate Catalyst Bullish Impact 65
Health Canada Approves GSK's Hibsago (bepirovirsen) for Chronic Hepatitis B
Health Canada has approved GSK's Hibsago (bepirovirsen) for the treatment of chronic hepatitis B in adults. This is a significant regulatory milestone for GSK, as it expands the co…
Nov 2, 2026 Corporate Catalyst Neutral Impact 55
Alfasigma Announces GSK Presentations on Linerixibat at AASLD The Liver Meeting 2026
Alfasigma announced that GSK will present five analyses on linerixibat for primary biliary cholangitis (PBC) at the AASLD Liver Meeting in November 2026. This filing is a forward-l…
Oct 30, 2026 Corporate Catalyst Bearish Impact 55
India Implements Price Caps on Cancer Drugs
India has introduced new trade margin caps on 137 cancer medications, effective November 9, 2026. This regulatory change could significantly impact pharmaceutical companies operati…
Oct 30, 2026 Corporate Catalyst Bearish Impact 75
Analysts Adjust Ratings and Price Targets for GSK
Jefferies downgraded GSK from 'Buy' to 'Hold' and significantly cut its price target, while Barclays also reduced its price target, maintaining an 'Underweight' rating. These actio…
Oct 29, 2026 Corporate Catalyst Bearish Impact 65
Jefferies Downgrades GSK to 'Hold'
Jefferies downgraded GSK plc to 'Hold' and lowered its price target to 2100 pence after the company's Q3 financial results. This analyst action is significant because it reflects a…
Oct 28, 2026 Corporate Catalyst Bullish Impact 85
GSK Reports Strong Third Quarter 2026 Financial Results
GSK announced strong Q3 2026 financial results, with total sales up 5% and core EPS significantly beating analyst consensus. This positive performance, driven by a 15% increase in …
Oct 27, 2026 Corporate Catalyst Bullish Impact 65
GSK Plans to Nearly Double Clinical-Stage Cancer Drug Pipeline in 2027
GSK announced its intention to nearly double its clinical-stage cancer drug pipeline by 2027, indicating a significant strategic shift towards oncology. This move is important as i…
Oct 26, 2026 Corporate Catalyst Bullish Impact 75
GSK Announces Positive Phase Ib Data for Mocertatug Rezetecan in Ovarian Cancer
GSK announced updated positive Phase Ib data for mocertatug rezetecan (Mo-Rez) in platinum-resistant ovarian cancer, demonstrating a 62% objective response rate and a 12.2-month me…
Oct 20, 2026 Corporate Catalyst Bullish Impact 75
GSK shares are trading higher after the FDA approved Hibsago injection, in combination with existing antiviral therapy, to treat chronic hepatitis B virus infection in certain adults without cirrhosis.
The FDA approval of Hibsago for chronic hepatitis B is a significant positive catalyst for GSK. This expands their market reach in a substantial therapeutic area, potentially leadi…
Oct 19, 2026 Corporate Catalyst Bullish Impact 85
FDA Clears GSK Drug That Could Change How Certain Rectal Cancers Are Treated
The FDA's accelerated approval of GSK's Jemperli for stage II and III dMMR/MSI-H locally advanced rectal cancer is a significant corporate catalyst. This drug offers a groundbreaki…
Oct 18, 2026 Corporate Catalyst Bullish Impact 75
GSK, On Sunday, Announced First Global Phase Ib EMBOLD PanTumour-101 Data Showing Anti-Tumour Activity, Manageable Safety Profile For Ris-Rez In Relapsed ES-SCLC
This headline represents a significant corporate catalyst for GSK. Positive Phase Ib data, especially for a difficult-to-treat cancer like ES-SCLC, indicates a promising drug candi…
Oct 9, 2026 Corporate Catalyst Bullish Impact 55
Commonwealth Of Pennsylvania: Governor Shapiro Secures Over $800M Investment From GSK To Expand Operations, Creating Over 300 New Jobs; GSK Is Expanding Its Facilities In Upper Merion Township, With Construction Planned To Begin In 2027
The Commonwealth of Pennsylvania announced a significant investment of over $800 million from GSK for facility expansion in Upper Merion Township, which will create more than 300 n…
Sep 24, 2026 Corporate Catalyst Bullish Impact 75
GSK Says Health Canada Accepted Jemperli For Accelerated Review In Genetic Subtype Of Locally Advanced Rectal Cancer
The acceptance of Jemperli for accelerated review by Health Canada is a significant positive development for GSK. Accelerated review pathways are typically granted for drugs that a…
Sep 14, 2026 Corporate Catalyst Bullish Impact 85
Why Is GSK Stock Gaining Monday?
GSK released compelling Phase 3 data for Risvutatug Rezetecan (Ris-Rez) in small cell lung cancer, showing a 54% reduction in mortality risk and significantly extended median survi…
Sep 14, 2026 Corporate Catalyst Bullish Impact 85
GSK's Jideytro Achieves 94% Objective Response Rate At 15.2 Months Follow-Up In TKI-Naïve ROS1-Positive NSCLC, ARROS-1 Trial Shows
GSK reported impressive interim data for Jideytro in the ARROS-1 trial for ROS1-positive NSCLC. The 94% objective response rate and 90% progression-free rate at 12 months, along wi…
Sep 11, 2026 Corporate Catalyst Bearish Impact 55
GSK Says Plans To Stop Manufacturing At Co's Dresden, Germany Flu Vaccine Manufacturing Site In Summer 2027
GSK has announced plans to discontinue flu vaccine manufacturing at its Dresden, Germany facility by summer 2027. This move suggests a strategic re-evaluation of its global manufac…
Sep 1, 2026 Corporate Catalyst Bullish Impact 75
GSK Says Immune Response from mRNA Flu Shot Surpasses Licensed Competitors
GSK has reported strong mid-stage results for its mRNA seasonal influenza vaccine, showing superior immune responses against all tested strains compared to existing licensed vaccin…
Jul 30, 2026 Corporate Catalyst Bullish Impact 75
Relation Expands GSK Collaboration Worth Up To $110M In Upfront And Milestone Payments To Generate Large-Scale Human Cellular Perturbation Datasets For Disease Biology Research
This headline is a significant corporate catalyst for both Relation Therapeutics and GSK. For Relation, it provides substantial funding and validation for their cellular perturbati…
Jul 29, 2026 Corporate Catalyst Bullish Impact 65
GSK Announces Cabenuva Demonstrates Superiority To Daily Oral Therapy In Adolescents Living With HIV, As Viiv Healthcare Highlights New Long-Acting Injectable Data At AIDS 2026
GSK, through its joint venture ViiV Healthcare, announced positive clinical trial results for Cabenuva, a long-acting injectable HIV treatment, showing its superiority to daily ora…
Jul 28, 2026 Corporate Catalyst Bullish Impact 85
GSK Races To Protect Profits Before Its HIV Blockbuster Faces Generic Rivals
GSK announced better-than-expected second-quarter earnings and revenue, driving its stock up. The core of this filing is the launch of a $2.52 billion cost-savings program, 'Accele…
Jul 28, 2026 Corporate Catalyst Neutral Impact 55
GSK Investing £400M To Establish New R&D Center In Cambridge, U.K.
GSK announced a £400 million investment to build a new R&D center in Cambridge, UK, consolidating its existing R&D operations in the area. This move is significant as it underscore…
Jul 28, 2026 Corporate Catalyst Bullish Impact 92
GSK shares are trading higher after the company reported better-than-expected Q2 financial results and issued FY31 sales guidance above estimates.
This headline is a major positive catalyst for GSK. Better-than-expected Q2 results indicate strong current operational performance, while the raised FY31 sales guidance provides a…
Jul 28, 2026 Corporate Catalyst Neutral Impact 75
GSK FY2031 Revenue expected to be more than $53.204B vs $45.690B Est
GSK has announced an ambitious revenue projection for FY2031, forecasting over $53.204 billion, which is a significant uplift compared to the $45.690 billion analyst estimate. This…
Jul 28, 2026 Corporate Catalyst Bullish Impact 92
GSK Q2 Adj. EPS $1.35 Beats $1.27 Estimate, Sales $11.280B Beat $10.790B Estimate
GSK announced its Q2 earnings, reporting adjusted EPS of $1.35, which significantly beat the analyst consensus of $1.27. Additionally, the company's sales of $11.280 billion surpas…
Jul 28, 2026 Corporate Catalyst Bullish Impact 65
GSK Licensor Hansoh Pharma Announces Results From Second Phase III Trial For Ris-Rez In China; Study Met Its Primary Endpoint Of Progression-Free Survival In Relapsed Osteosarcoma
GSK's licensor, Hansoh Pharma, announced positive results from a second Phase III trial for Ris-Rez in China, specifically for relapsed osteosarcoma, which met its primary endpoint…
Jul 24, 2026 Corporate Catalyst Neutral Impact 55
GSK Canada Receives Approval For Shingrix Zoster Vaccine In Prefilled Syringe
GSK Canada announced the approval of its Shingrix vaccine in a prefilled syringe format. This development is significant because it streamlines the vaccine administration process b…
Jul 22, 2026 Corporate Catalyst Bullish Impact 85
GSK Wins FDA Approval For Jideytro To Treat Previously Treated ROS1-Positive Non-Small Cell Lung Cancer
GSK has secured early FDA approval for Jideytro, a ROS1 selective inhibitor, for a specific type of non-small cell lung cancer. This approval is significant because it comes ahead …
Jul 17, 2026 Corporate Catalyst Bearish Impact 75
GSK shares are trading lower after the company announced that it will cease further development of Camlipixant as a chronic cough treatment due to its failure to meet statistical significance in two clinical trials.
GSK has decided to discontinue the development of Camlipixant, a drug intended for refractory chronic cough, after it failed to achieve statistical significance in its CALM-1 and C…
Jul 17, 2026 Corporate Catalyst Bearish Impact 75
Disappointing Data Prompts GSK to Drop Cough Drug Development
GSK's decision to halt the development of camlipixant for refractory chronic cough is a negative catalyst for the company. The inconsistent Phase 3 trial data, particularly the fai…
Jul 17, 2026 Corporate Catalyst Bearish Impact 85
GSK Plans To Stop Further Development Of Camlipixant In Refractory Chronic Cough As Camlipixant 25mg Twice Daily Failed To Meet Statistical Significance In CALM-1, CALM-2 Clinical Trials
GSK has decided to stop further development of Camlipixant, its investigational drug for refractory chronic cough, following the failure of its 25mg twice-daily dose to achieve sta…
Jul 13, 2026 Corporate Catalyst Bullish Impact 75
GSK's Jemperli May Help Some Rectal Cancer Patients Avoid Surgery
GSK announced positive interim results from its Phase 2 AZUR-1 trial for Jemperli in dMMR/MSI-H locally advanced rectal cancer. The drug achieved a sustained clinical complete resp…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.